Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ESRRB | O95718 | 1/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176327 | 0.85 | AAK1 (0.51) | AAK1ROCK2MAPT | |
| SCHEMBL20176364 | 0.80 | AAK1 (0.60) | AAK1ROCK2ALDH1A1MAPTRAB9A | |
| SCHEMBL19946077 | 0.80 | AAK1 (0.56) | AAK1ROCK2ALDH1A1MAPTRAB9A | |
| SCHEMBL19946079 | 0.79 | AAK1 (0.53) | AAK1ROCK2ALDH1A1MAPTRAB9A | |
| SCHEMBL19946056 | 0.78 | AAK1 (0.61) | AAK1ROCK2 | |
| SCHEMBL26768871 | 0.76 | ESR1 (0.43) | ALDH1A1MAPTRAB9AHSP90AA1ESR1 | |
| SCHEMBL802750 | 0.76 | MAOA (0.49) | ALDH1A1MAPTRAB9AESR1ESR2 | |
| SCHEMBL30577530 | 0.76 | MAOA (0.49) | ALDH1A1MAPTRAB9AESR1ESR2 | |
| SCHEMBL3198655 | 0.74 | ALDH1A1 (0.41) | ROCK2ALDH1A1MAPTRAB9AHSP90AA1 | |
| SCHEMBL26768220 | 0.72 | MAOB (0.42) | AAK1ROCK2ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | AAK1, NCK1, ADCK1 | AAK1 1/4885ROCK2 966/4885ALDH1A1 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.